Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be
evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.
Phase:
N/A
Details
Lead Sponsor:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation